HK1085388A1 - Use of bv8 and/or eg-vegf to promote hematopoiesis bv8 / eg-vegf - Google Patents
Use of bv8 and/or eg-vegf to promote hematopoiesis bv8 / eg-vegfInfo
- Publication number
- HK1085388A1 HK1085388A1 HK06105401.6A HK06105401A HK1085388A1 HK 1085388 A1 HK1085388 A1 HK 1085388A1 HK 06105401 A HK06105401 A HK 06105401A HK 1085388 A1 HK1085388 A1 HK 1085388A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- vegf
- promote hematopoiesis
- hematopoiesis
- promote
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0669—Bone marrow stromal cells; Whole bone marrow
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Developmental Biology & Embryology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45446203P | 2003-03-12 | 2003-03-12 | |
US51139003P | 2003-10-14 | 2003-10-14 | |
PCT/US2004/007622 WO2004081229A2 (fr) | 2003-03-12 | 2004-03-12 | Compositions a activite hematopoietique et immunitaire |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1085388A1 true HK1085388A1 (en) | 2006-08-25 |
Family
ID=32994559
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06105401.6A HK1085388A1 (en) | 2003-03-12 | 2006-05-09 | Use of bv8 and/or eg-vegf to promote hematopoiesis bv8 / eg-vegf |
HK15101221.2A HK1200715A1 (en) | 2003-03-12 | 2015-02-04 | Use of bv8 and/or eg-vegf to promote hematopoiesis bv8 / eg-vegf |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15101221.2A HK1200715A1 (en) | 2003-03-12 | 2015-02-04 | Use of bv8 and/or eg-vegf to promote hematopoiesis bv8 / eg-vegf |
Country Status (11)
Country | Link |
---|---|
US (3) | US7632810B2 (fr) |
EP (2) | EP2526960A1 (fr) |
JP (3) | JP4912144B2 (fr) |
KR (2) | KR101294959B1 (fr) |
CN (2) | CN102225194B (fr) |
AU (2) | AU2004219592C1 (fr) |
CA (1) | CA2515288A1 (fr) |
HK (2) | HK1085388A1 (fr) |
MX (1) | MXPA05009743A (fr) |
NZ (1) | NZ541480A (fr) |
WO (1) | WO2004081229A2 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020172678A1 (en) * | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
US6485938B1 (en) | 1999-11-16 | 2002-11-26 | Zymogenetics, Inc. | Nucleic acid molecules that encodes human Zven1 |
US7060278B2 (en) | 2001-08-29 | 2006-06-13 | Genentech, Inc. | Bv8 nucleic acids and polypeptides with mitogenic activity |
JP2006514683A (ja) | 2002-10-07 | 2006-05-11 | ザイモジェネティクス,インコーポレイティド | ヒトzvenアンタゴニストの使用 |
EP2526960A1 (fr) | 2003-03-12 | 2012-11-28 | Genentech, Inc. | Utilisation de BV8 et/ou de EG-VEGF pour promouvoir l'hématopoièse |
US20080219985A1 (en) | 2005-09-13 | 2008-09-11 | Thompson Penny J | Prok2 antagonists and methods of use |
US20080050814A1 (en) * | 2006-06-05 | 2008-02-28 | Cryo-Cell International, Inc. | Procurement, isolation and cryopreservation of fetal placental cells |
US20080064098A1 (en) * | 2006-06-05 | 2008-03-13 | Cryo-Cell International, Inc. | Procurement, isolation and cryopreservation of maternal placental cells |
MX2009005398A (es) * | 2006-11-21 | 2009-08-20 | Kalobios Pharmaceuticals Inc | Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf. |
CL2008002782A1 (es) * | 2007-09-21 | 2009-07-31 | Genentech Inc | Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular. |
WO2010046889A1 (fr) * | 2008-10-23 | 2010-04-29 | Quark Pharmaceuticals, Inc. | Procédés de distribution d'arnsi à des cellules de moelle osseuse et leurs utilisations |
EP4389764A2 (fr) * | 2012-11-05 | 2024-06-26 | Regeneron Pharmaceuticals, Inc. | Animaux non humains génétiquement modifiés et leurs procédés d'utilisation |
US11071754B2 (en) * | 2013-03-11 | 2021-07-27 | Case Western Reserve University | Method of generating tumor-specific T cells |
RU2662944C1 (ru) * | 2017-02-17 | 2018-07-31 | Общество с ограниченной ответственностью "Группа развития "АПЕКС" | Средство для лечения состояний человеческого организма, связанных с уменьшением уровня экспрессии гена prok 1 и/или уменьшением количества белка прокинетицина 1 на основе генно-терапевтических субстанций с геном prok 1, способ получения и использования |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4109496A (en) | 1977-12-20 | 1978-08-29 | Norris Industries | Trapped key mechanism |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
EP0052322B1 (fr) | 1980-11-10 | 1985-03-27 | Gersonde, Klaus, Prof. Dr. | Méthode de préparation de vésicules lipidiques par traitement aux ultra-sons, utilisation de ce procédé et l'appareillage ainsi utilisé |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
EP0088046B1 (fr) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipides en phase aqueuse |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
US4943529A (en) | 1982-05-19 | 1990-07-24 | Gist-Brocades Nv | Kluyveromyces as a host strain |
EP0102324A3 (fr) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipides et composés tensio-actifs en phase aqueuse |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4643980A (en) * | 1983-06-13 | 1987-02-17 | Info-Chem, Inc. | Glutaraldehyde indicator |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
AU3145184A (en) | 1983-08-16 | 1985-02-21 | Zymogenetics Inc. | High expression of foreign genes in schizosaccharomyces pombe |
DE3486459D1 (de) | 1983-09-26 | 1997-12-11 | Udo Dr Med Ehrenfeld | Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
EP0143949B1 (fr) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Composition pharmaceutique contenant de l'urokinase |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
EP0206448B1 (fr) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hémoglobine liée à un poly(oxyde d'alkylène) |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946783A (en) | 1987-01-30 | 1990-08-07 | President And Fellows Of Harvard College | Periplasmic protease mutants of Escherichia coli |
US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
EP0321196A3 (fr) | 1987-12-18 | 1990-07-18 | Mycogen Plant Science, Inc. | Activateur de transcription du gène 780 d |
EP0397687B1 (fr) | 1987-12-21 | 1994-05-11 | The University Of Toledo | Transformation par l'agrobacterium de graines de plantes de germination |
AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
US5240848A (en) | 1988-11-21 | 1993-08-31 | Monsanto Company | Dna sequences encoding human vascular permeability factor having 189 amino acids |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
EP0394538B1 (fr) | 1989-04-28 | 1996-10-16 | Rhein Biotech Gesellschaft Für Neue Biotechnologische Prozesse Und Produkte Mbh | Cellules de levure du genre schwanniomyces |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
US5332671A (en) | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
EP0402226A1 (fr) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Vecteurs de transformation de la levure yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
EP0739904A1 (fr) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Réactifs bispécifiques pour le traitement du SIDA |
DK168302B1 (da) | 1989-06-29 | 1994-03-07 | Danisco | Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller |
FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
EP0502036B1 (fr) | 1989-11-22 | 1995-12-20 | Genentech, Inc. | Peptide associe a la latence et utilisations |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
EP0586505A1 (fr) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Anticorps d'heteroconjugues pour le traitement des infections a l'hiv |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
CA2103059C (fr) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Methode de production d'anticorps humanises |
WO1993006213A1 (fr) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production d'anticorps chimeriques - une approche combinatoire |
WO1993008829A1 (fr) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions induisant la destruction de cellules infectees par l'hiv |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5561053A (en) | 1994-08-05 | 1996-10-01 | Genentech, Inc. | Method for selecting high-expressing host cells |
WO2000053753A2 (fr) | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Activation ou inhibition de l'angiogenese et de la cardiovascularisation |
WO2000073454A1 (fr) | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci |
AUPN263895A0 (en) * | 1995-04-28 | 1995-05-25 | Bradley, Christopher Mark | Apparatus and method for producing bone graft material |
US6020473A (en) | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
US6013780A (en) | 1996-09-06 | 2000-01-11 | Technion Research & Development Co. Ltd. | VEGF145 expression vectors |
WO2002000690A2 (fr) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese |
CA2192004C (fr) * | 1996-12-04 | 2006-05-02 | Chris Parkinson | Essai de diagnostic pour vaginose bacterienne |
WO1999006550A2 (fr) | 1997-08-01 | 1999-02-11 | Genset | Marqueurs sequences 5' exprimes pour proteines secretees exprimees dans la prostate |
CA2328895A1 (fr) | 1998-06-02 | 1999-12-09 | Genentech, Inc. | Proteines membranaires et acides nucleiques codant ces proteines |
US7264801B2 (en) * | 1998-08-11 | 2007-09-04 | Genentech, Inc. | EG-VEGF nucleic acids and polypeptides and method of use |
US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
US20030027998A1 (en) * | 1998-10-30 | 2003-02-06 | Holtzman Douglas A. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
CA2362924A1 (fr) | 1999-03-01 | 2000-09-08 | Millennium Pharmaceuticals, Inc. | Proteines secretees et acides nucleiques codant pour elles |
ES2265931T3 (es) | 1999-04-16 | 2007-03-01 | Genentech, Inc. | Variantes del factor de crecimiento celular endotelial vascular (vegf) y sus usos. |
AU5151100A (en) | 1999-05-19 | 2000-12-05 | Incyte Genomics, Inc. | Extracellular signaling molecules |
AU3246100A (en) | 1999-06-02 | 2000-12-28 | Genentech Inc. | Methods and compositions for inhibiting neoplastic cell growth |
US6485938B1 (en) * | 1999-11-16 | 2002-11-26 | Zymogenetics, Inc. | Nucleic acid molecules that encodes human Zven1 |
EP1230362A2 (fr) | 1999-11-16 | 2002-08-14 | ZymoGenetics, Inc. | Proteines humaines zven |
EP1690872A3 (fr) | 1999-12-01 | 2006-08-23 | Genentech, Inc. | Composition et procédés de diagnostic de tumeurs |
AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
JP2004516013A (ja) | 2000-07-20 | 2004-06-03 | ジェネンテック・インコーポレーテッド | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
EP1354040A2 (fr) | 2000-07-20 | 2003-10-22 | Genentech, Inc. | Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides |
AU2002230778A1 (en) | 2000-11-03 | 2002-05-15 | The Regents Of The University Of California | Prokineticin polypeptides, related compositions and methods |
US20030171306A1 (en) * | 2001-06-04 | 2003-09-11 | Davis Stephen Thomas | Cancer treatment method |
US7060278B2 (en) * | 2001-08-29 | 2006-06-13 | Genentech, Inc. | Bv8 nucleic acids and polypeptides with mitogenic activity |
JP2006514683A (ja) * | 2002-10-07 | 2006-05-11 | ザイモジェネティクス,インコーポレイティド | ヒトzvenアンタゴニストの使用 |
EP2526960A1 (fr) | 2003-03-12 | 2012-11-28 | Genentech, Inc. | Utilisation de BV8 et/ou de EG-VEGF pour promouvoir l'hématopoièse |
CL2008002782A1 (es) | 2007-09-21 | 2009-07-31 | Genentech Inc | Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular. |
-
2004
- 2004-03-12 EP EP12177912A patent/EP2526960A1/fr not_active Withdrawn
- 2004-03-12 KR KR1020117016764A patent/KR101294959B1/ko not_active IP Right Cessation
- 2004-03-12 AU AU2004219592A patent/AU2004219592C1/en not_active Ceased
- 2004-03-12 NZ NZ541480A patent/NZ541480A/xx not_active IP Right Cessation
- 2004-03-12 WO PCT/US2004/007622 patent/WO2004081229A2/fr active Application Filing
- 2004-03-12 CA CA002515288A patent/CA2515288A1/fr not_active Abandoned
- 2004-03-12 CN CN201110162095.3A patent/CN102225194B/zh not_active Expired - Fee Related
- 2004-03-12 US US10/549,241 patent/US7632810B2/en not_active Expired - Fee Related
- 2004-03-12 EP EP04720416.9A patent/EP1615659B1/fr not_active Expired - Lifetime
- 2004-03-12 CN CN201410272660.5A patent/CN104001158A/zh active Pending
- 2004-03-12 JP JP2006507127A patent/JP4912144B2/ja not_active Expired - Fee Related
- 2004-03-12 KR KR1020057016887A patent/KR101118340B1/ko not_active IP Right Cessation
- 2004-03-12 MX MXPA05009743A patent/MXPA05009743A/es active IP Right Grant
-
2006
- 2006-05-09 HK HK06105401.6A patent/HK1085388A1/xx not_active IP Right Cessation
-
2009
- 2009-11-03 US US12/611,397 patent/US8257702B2/en not_active Expired - Fee Related
-
2010
- 2010-07-05 JP JP2010153450A patent/JP2011004745A/ja active Pending
- 2010-10-29 AU AU2010238554A patent/AU2010238554A1/en not_active Abandoned
-
2012
- 2012-08-03 US US13/566,920 patent/US8858936B2/en not_active Expired - Fee Related
-
2015
- 2015-01-05 JP JP2015000262A patent/JP2015119708A/ja active Pending
- 2015-02-04 HK HK15101221.2A patent/HK1200715A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP1615659A2 (fr) | 2006-01-18 |
JP2015119708A (ja) | 2015-07-02 |
CA2515288A1 (fr) | 2004-09-23 |
AU2010238554A1 (en) | 2010-11-18 |
JP4912144B2 (ja) | 2012-04-11 |
NZ541480A (en) | 2008-03-28 |
KR20110097965A (ko) | 2011-08-31 |
HK1200715A1 (en) | 2015-08-14 |
KR101118340B1 (ko) | 2012-04-12 |
AU2004219592A1 (en) | 2004-09-23 |
US20060217301A1 (en) | 2006-09-28 |
KR101294959B1 (ko) | 2013-08-09 |
CN104001158A (zh) | 2014-08-27 |
CN102225194B (zh) | 2014-07-16 |
JP2007520998A (ja) | 2007-08-02 |
US20130195885A1 (en) | 2013-08-01 |
EP2526960A1 (fr) | 2012-11-28 |
JP2011004745A (ja) | 2011-01-13 |
US7632810B2 (en) | 2009-12-15 |
MXPA05009743A (es) | 2006-03-09 |
CN102225194A (zh) | 2011-10-26 |
US8257702B2 (en) | 2012-09-04 |
KR20050114229A (ko) | 2005-12-05 |
WO2004081229A2 (fr) | 2004-09-23 |
US8858936B2 (en) | 2014-10-14 |
AU2004219592C1 (en) | 2011-02-24 |
AU2004219592B2 (en) | 2010-07-29 |
WO2004081229A3 (fr) | 2004-10-28 |
EP1615659B1 (fr) | 2014-04-16 |
US20100310555A1 (en) | 2010-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1200715A1 (en) | Use of bv8 and/or eg-vegf to promote hematopoiesis bv8 / eg-vegf | |
ZA200600387B (en) | Hydrolytically-resistant bornon-containing therapeutics and methods of use | |
EP1689348A4 (fr) | Composition d'oligosaccharides et leur utilisation dans le traitement d'infection | |
HK1084949A1 (en) | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | |
AU2002305396A8 (en) | Use of dihydropyrazoles to increase erythropoietin and vasculari zation | |
EP1750757A4 (fr) | Procedes de purification de la chondroitinase et formulations stables de cette derniere | |
HK1109581A1 (en) | Pharmaceutical use of graptopetalum and related plants | |
EP1615880A4 (fr) | Preparation et purification de trans-capsaicine synthetique | |
EP1625141A4 (fr) | Compositions a base de grp94 et procedes d'utilisation associes | |
PL1750507T3 (pl) | Preparat do wywoływania zwiększonej produkcji związków biologicznie czynnych w roślinach oraz jego zastosowanie | |
AU2003268484A8 (en) | Delivery of therapeutics to the brain and spinal cord | |
EP1601348A4 (fr) | Compositions et methodes presentant une activite therapeutique amelioree | |
EP1668464A4 (fr) | Utilisation d'une technologie de transformation pour elaborer des descriptions semantiques | |
EP1666046A4 (fr) | Utilisation de la n-acetyl-d-aminoglycosamine pour la preparation de medicaments de traitement du cancer et des metastases | |
GB0308399D0 (en) | Improvements in and relating to kettles | |
IL178420A0 (en) | Formulations and methods to prepare inhalable buffered methacholine chloride solutions | |
GB2421022B (en) | Use of bacteria to produce spinel nanoparticles | |
GB2405878B (en) | Improvements in and relating to weatherboarding | |
HK1073141A1 (en) | Use of fiber structure having anti-trichomonad and anti-spores of trichomonad property | |
GB0311292D0 (en) | Improvements in and relating to the movement of metal | |
AU2003265393A8 (en) | Use of certain n-acylethanolamines to achieve ethylene- and cytokinin-like effects in plants and fungi | |
GB0205395D0 (en) | Materials and methods relating to the treatment of lymphoma | |
GB0207596D0 (en) | Improvements in or relating to patient support structures and their use | |
AU2003274911A8 (en) | Mrbs as modifiers of the rb pathway and methods of use | |
GB0327452D0 (en) | Improvements in and relating to the design and manufacture of food trays |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190310 |